FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1559739015> ?p ?o ?g. }

• W1559739015 endingPage "76" @default.
• W1559739015 startingPage "64" @default.
• W1559739015 abstract "ObjectivesA proportion of HIV-positive people have condomless sex. Antiretroviral treatment (ART) reduces infectiousness, but a substantial proportion of HIV-diagnosed people are not yet on ART. We describe baseline self-reported risk behaviours in ART-naive Strategic Timing of AntiRetroviral Treatment (START) trial participants.MethodsAll START participants completed a risk behaviour questionnaire. Data were collected on sociodemographics, lifestyle factors, health and wellbeing status and clinical status. Recent sexual behaviour and HIV transmission beliefs in the context of ART were also assessed. The primary interest was in condomless sex with serodifferent partners (CLS-D) in the past two months.ResultsA total of 4601 of 4685 HIV-positive participants (98%) completed the questionnaire [2559 men who have sex with men (MSM), 803 heterosexual men and 1239 women]. Region of recruitment was Europe/Israel, 33%; South America/Mexico, 25%; Africa, 22%; other, 21%. Median age was 36 years [interquartile range (IQR) 29, 44 years]. Forty-five per cent reported white ethnicity and 31% black ethnicity. Two per cent had HIV viral load < 50 HIV-1 RNA copies/mL. Seventeen per cent (767 of 4601) reported CLS-D; 20% of MSM compared with 10% of heterosexual men and 14% of women. MSM were also more likely to report multiple CLS-D partners. Possible risk limitation measures (reported by more than half of those who had CLS-D) were seropositioning (receptive anal CLS-D only) or withdrawal (insertive anal CLS-D always without ejaculation). CLS-D was more commonly reported by participants from South America/Mexico and North America compared with Europe; among heterosexual men and women CLS-D was also more commonly reported among participants from Africa compared with Europe. Knowledge of ART impact on transmission risk was low.ConclusionsA substantial minority recruited to the START study reported CLS-D at baseline. CLS-D reporting was higher in MSM than heterosexuals and varied significantly according to region of recruitment. A substantial proportion of MSM reporting CLS-D appear to take transmission risk limitation measures." @default.
• W1559739015 created "2016-06-24" @default.
• W1559739015 creator A5005880135 @default.
• W1559739015 creator A5008623230 @default.
• W1559739015 creator A5020940696 @default.
• W1559739015 creator A5029552923 @default.
• W1559739015 creator A5044013680 @default.
• W1559739015 creator A5048403813 @default.
• W1559739015 creator A5050538872 @default.
• W1559739015 creator A5052362702 @default.
• W1559739015 creator A5062323483 @default.
• W1559739015 creator A5080460240 @default.
• W1559739015 creator A5086146203 @default.
• W1559739015 date "2015-02-25" @default.
• W1559739015 modified "2023-10-03" @default.
• W1559739015 title "Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial" @default.
• W1559739015 cites W1964951852 @default.
• W1559739015 cites W1969861729 @default.
• W1559739015 cites W1973112287 @default.
• W1559739015 cites W1973540642 @default.
• W1559739015 cites W1975425093 @default.
• W1559739015 cites W1977900451 @default.
• W1559739015 cites W1978013134 @default.
• W1559739015 cites W1982721121 @default.
• W1559739015 cites W1989538099 @default.
• W1559739015 cites W1997867299 @default.
• W1559739015 cites W2008563603 @default.
• W1559739015 cites W2009782089 @default.
• W1559739015 cites W2024983781 @default.
• W1559739015 cites W2035703449 @default.
• W1559739015 cites W2044072736 @default.
• W1559739015 cites W2062759951 @default.
• W1559739015 cites W2082024776 @default.
• W1559739015 cites W2087440321 @default.
• W1559739015 cites W2087828758 @default.
• W1559739015 cites W2095673016 @default.
• W1559739015 cites W2112669742 @default.
• W1559739015 cites W2117128648 @default.
• W1559739015 cites W2121167697 @default.
• W1559739015 cites W2146467151 @default.
• W1559739015 cites W2148750104 @default.
• W1559739015 cites W2152505869 @default.
• W1559739015 cites W2314461521 @default.
• W1559739015 cites W2408763107 @default.
• W1559739015 doi "https://doi.org/10.1111/hiv.12235" @default.
• W1559739015 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4341939" @default.
• W1559739015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25711325" @default.
• W1559739015 hasPublicationYear "2015" @default.
• W1559739015 type Work @default.
• W1559739015 sameAs 1559739015 @default.
• W1559739015 citedByCount "13" @default.
• W1559739015 countsByYear W15597390152015 @default.
• W1559739015 countsByYear W15597390152016 @default.
• W1559739015 countsByYear W15597390152017 @default.
• W1559739015 countsByYear W15597390152018 @default.
• W1559739015 countsByYear W15597390152019 @default.
• W1559739015 countsByYear W15597390152020 @default.
• W1559739015 crossrefType "journal-article" @default.
• W1559739015 hasAuthorship W1559739015A5005880135 @default.
• W1559739015 hasAuthorship W1559739015A5008623230 @default.
• W1559739015 hasAuthorship W1559739015A5020940696 @default.
• W1559739015 hasAuthorship W1559739015A5029552923 @default.
• W1559739015 hasAuthorship W1559739015A5044013680 @default.
• W1559739015 hasAuthorship W1559739015A5048403813 @default.
• W1559739015 hasAuthorship W1559739015A5050538872 @default.
• W1559739015 hasAuthorship W1559739015A5052362702 @default.
• W1559739015 hasAuthorship W1559739015A5062323483 @default.
• W1559739015 hasAuthorship W1559739015A5080460240 @default.
• W1559739015 hasAuthorship W1559739015A5086146203 @default.
• W1559739015 hasBestOaLocation W15597390151 @default.
• W1559739015 hasConcept C118552586 @default.
• W1559739015 hasConcept C119060515 @default.
• W1559739015 hasConcept C119599485 @default.
• W1559739015 hasConcept C119767625 @default.
• W1559739015 hasConcept C126322002 @default.
• W1559739015 hasConcept C127413603 @default.
• W1559739015 hasConcept C137403100 @default.
• W1559739015 hasConcept C142462285 @default.
• W1559739015 hasConcept C144024400 @default.
• W1559739015 hasConcept C149923435 @default.
• W1559739015 hasConcept C150966472 @default.
• W1559739015 hasConcept C151730666 @default.
• W1559739015 hasConcept C190729725 @default.
• W1559739015 hasConcept C19165224 @default.
• W1559739015 hasConcept C2776939746 @default.
• W1559739015 hasConcept C2776983459 @default.
• W1559739015 hasConcept C2779343474 @default.
• W1559739015 hasConcept C2993143319 @default.
• W1559739015 hasConcept C3013748606 @default.
• W1559739015 hasConcept C3019165603 @default.
• W1559739015 hasConcept C512399662 @default.
• W1559739015 hasConcept C71924100 @default.
• W1559739015 hasConcept C74909509 @default.
• W1559739015 hasConcept C761482 @default.
• W1559739015 hasConcept C86803240 @default.
• W1559739015 hasConceptScore W1559739015C118552586 @default.
• W1559739015 hasConceptScore W1559739015C119060515 @default.
• W1559739015 hasConceptScore W1559739015C119599485 @default.

• next